Found 10 Enz. Inhib. hit(s) with Target = 'Endothelial PAS domain-containing protein 1' and Ligand = 'BDBM373008' TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
3D Structure (crystal)TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: 8.5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: 12nMAssay Description:Inhibition of N-(3-Chlorophenyl-4,6-t2)-4-nitrobenzo[c][1,2,5]oxadiazol-5-amine binding to his-tagged HIF-2alpha PAS-B domain (unknown origin) measur...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: 12nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: 17nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataEC50: 27nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells co-expressing HIF responsive element after 24 hrs by ONE-Glo luciferase reporter gene assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataEC50: 27nMAssay Description:Inhibition of HIF-2alpha (unknown origin) expressed in human 786-O cells measured after 24 hrs by one-glo luciferase reporter gene assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataEC50: 46nMAssay Description:Inhibition of HIF-2alpha (unknown origin) expressed in human 786-O cells assessed as reduction in VEGFA level incubated for 20 hrs prior to compound ...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataEC50: 158nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells assessed as free plasma adjusted EC50 for reduction in VEGFA concentration after 24 hrs by ELI...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataEC50: 41nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells assessed as reduction in VEGFA concentration after 24 hrs by ELISAMore data for this Ligand-Target Pair
